[go: up one dir, main page]

AU2001250212A1 - Rhamm peptide conjugates - Google Patents

Rhamm peptide conjugates

Info

Publication number
AU2001250212A1
AU2001250212A1 AU2001250212A AU5021201A AU2001250212A1 AU 2001250212 A1 AU2001250212 A1 AU 2001250212A1 AU 2001250212 A AU2001250212 A AU 2001250212A AU 5021201 A AU5021201 A AU 5021201A AU 2001250212 A1 AU2001250212 A1 AU 2001250212A1
Authority
AU
Australia
Prior art keywords
peptide conjugates
rhamm peptide
rhamm
conjugates
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001250212A
Inventor
Terrance Jimmy Sereda
Deanna June Wiebe
Ashley Martin Williams
B. Michael R. Woloski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cangene Corp
Original Assignee
Cangene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cangene Corp filed Critical Cangene Corp
Publication of AU2001250212A1 publication Critical patent/AU2001250212A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001250212A 2000-04-20 2001-04-20 Rhamm peptide conjugates Abandoned AU2001250212A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19861300P 2000-04-20 2000-04-20
US60/198,613 2000-04-20
PCT/CA2001/000533 WO2001080899A2 (en) 2000-04-20 2001-04-20 Rhamm peptide conjugates

Publications (1)

Publication Number Publication Date
AU2001250212A1 true AU2001250212A1 (en) 2001-11-07

Family

ID=22734084

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001250212A Abandoned AU2001250212A1 (en) 2000-04-20 2001-04-20 Rhamm peptide conjugates

Country Status (5)

Country Link
US (1) US20040037834A1 (en)
EP (1) EP1274461A2 (en)
AU (1) AU2001250212A1 (en)
CA (1) CA2406593A1 (en)
WO (1) WO2001080899A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911429B2 (en) 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
DE60325906D1 (en) 2003-08-08 2009-03-05 Amgen Fremont Inc ANTIBODIES TO PARATH-HORMONE (PTH) AND ITS USES
US7607592B1 (en) 2004-11-08 2009-10-27 Kim Sang B Accessories for water and beverage bottles
JP5140579B2 (en) * 2005-06-08 2013-02-06 カンジェーン コーポレイション Hyaluronic acid-binding peptide enhances defense against pathogens
WO2008140586A2 (en) * 2006-11-21 2008-11-20 The Regents Of The University Of California Modulation of rhamm (cd168) for selective adipose tissue development
US20100062000A1 (en) * 2006-11-21 2010-03-11 The Regents Of The University Of California Rhamm, a Co-Receptor and Its Interactions with Other Receptors in Cancer Cell Motility and the Identification of Cancer Prognitor Cell Populations
USD590658S1 (en) 2007-03-05 2009-04-21 Richard Pola & Associates, Inc. Cup with spritzing mechanism
AU2009270405B2 (en) 2008-06-30 2014-06-05 Esbatech, An Alcon Biomedical Research Unit Llc Functionalized polypeptides
US8530189B2 (en) * 2008-10-16 2013-09-10 Kathleen Cogan Farinas Sustained drug delivery system
EP2349339A4 (en) * 2008-10-16 2015-01-07 Kathleen Cogan Farinas Sustained drug delivery system
US10494402B2 (en) 2012-11-25 2019-12-03 The Regents Of The University Of California Peptides that stimulate subcutaneous adipogenesis
GB201400994D0 (en) * 2014-01-21 2014-03-05 Ucl Business Plc Drug delivery system
US10844102B2 (en) 2014-05-28 2020-11-24 The Regents Of The University Of California Peptides, compositions, and methods for stimulating subcutaneous adipogenesis
WO2016151478A1 (en) 2015-03-20 2016-09-29 London Health Sciences Centre Research Inc. Stapled peptides and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06504912A (en) * 1991-01-14 1994-06-09 ニューヨーク・ユニバーシティ Cytokine-inducing protein TSG-6, DNA encoding the TSG-6 protein, and use of the TSG-6 protein
GB9207949D0 (en) * 1992-04-09 1992-05-27 Univ Manitoba Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility
KR970705401A (en) * 1994-08-30 1997-10-09 사무엘 시몬 에스큘라이 HYALURONIC ACID AND DERIVATIVES FOR MODULATION OF CELLULAR ACTIVITY FOR ADJUSTING CELL ACTIVITY
CA2205771C (en) * 1997-05-22 2002-05-14 Hyal Pharmaceutical Corporation Improved delivery of disease modifiers
CA2237051A1 (en) * 1997-12-19 1999-06-19 Eva A. Turley Enhanced affinity hyaluronan binding peptides

Also Published As

Publication number Publication date
EP1274461A2 (en) 2003-01-15
WO2001080899A2 (en) 2001-11-01
WO2001080899A3 (en) 2002-09-06
US20040037834A1 (en) 2004-02-26
CA2406593A1 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
AU2002233230A1 (en) Erythropoietin conjugates
AU2001262237A1 (en) Reflector
AU2003253048A1 (en) Tubulysin conjugates
AU2001254546A1 (en) Aminopiperidines
AU2001240026A1 (en) Camptothecin conjugates
AU2001220246A1 (en) Neckphone
AU2001239310A1 (en) Decahydro-isoquinolines
AU2001250212A1 (en) Rhamm peptide conjugates
AU2001271869A1 (en) Conveyor bracket
AU2001262689A1 (en) Oligopeptides
AU2001240791A1 (en) Sequence
AU2001289307A1 (en) Chemically-modified myelopoietin conjugates
AU5903000A (en) Novel anti-thrombin peptide
AU2001246864A1 (en) Hypotensors
AU2001226668A1 (en) Crankshaft-starter-generator
AU2002216749A1 (en) Chemokine conjugates
EP1201403A3 (en) Electrofusible units
AU2001282521A1 (en) OCT preparations
AU4308001A (en) Transition metal-cyclopentadienyl-tropane conjugates
AU2001257009A1 (en) Enhanced hyperlink
AU2002239747A1 (en) Cystoskeleton-associated proteins
AU5090000A (en) Barriers
AU2001278975A1 (en) Alpha-conotoxin peptides
AU2002215145A1 (en) Dual orientation connector
AU2002240841A1 (en) Cytostatic-glycoconjugates having specifically cleavable peptidiclinking units